Market Overview

ISI Group Downgrades Bruker To Neutral

Related BRKR
Bruker Corp Has 'Great Story,' But It's Not Time To Jump In Yet
Bruker Introduces MALDI Tissuetyper Solution With New High Speed RapifleX MALDI-TOF MS System For Anatomical Pathology Research

Analysts at ISI Group downgraded Bruker (NASDAQ: BRKR) from “buy” to “neutral.”

Bruker shares have surged 44.61% over the past 52 weeks, while the S&P 500 index has gained 19.69% in the same period.

Bruker's shares fell 2.20% to close at $24.02 yesterday.

Latest Ratings for BRKR

Nov 2015Stifel NicolausInitiates Coverage onBuy
Nov 2015Leerink SwannMaintainsOutperform
Sep 2015Morgan StanleyInitiates Coverage onEqual-weight

View More Analyst Ratings for BRKR
View the Latest Analyst Ratings

Posted-In: ISI GroupDowngrades Analyst Ratings


Related Articles (BRKR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters